Classic Hodgkin lymphoma has always been a bit of a drama queen. Under the microscope, the actual cancer cells - Hodgkin and Reed-Sternberg, or HRS cells - are weirdly rare, while the surrounding tissue looks packed with immune cells, like security showed up in force and then somehow let the burglar redecorate the place. In this new transcriptome study, researchers sorted HRS cells from primary tumors and read out which genes were switched on and off. What they found was a pretty wild two-part plot: these cells seem stuck in an aborted identity crisis, and they also appear to duck natural killer, or NK, cell surveillance by turning down molecules such as CD48 that would normally help NK cells recognize trouble (Roshal et al.).
The cancer cell with commitment issues
HRS cells come from B cells, specifically germinal center B cells, but they do not behave like tidy, well-adjusted B cells anymore. This paper suggests they have wandered partway toward becoming plasma cells, which are the body’s antibody factories, then stalled out halfway like someone moving apartments and deciding to live in the hallway.
That matters because plasma cells are built for heavy protein production. When a cell starts gearing up to make lots of proteins, its internal folding machinery can get stressed. Enter the unfolded protein response, or UPR. Think of it like the quality-control team in a factory realizing half the boxes are coming off the line upside down and somebody needs to start shouting. The authors found a strong UPR signature in HRS cells, something seen in plasma-cell diseases like multiple myeloma, but not nearly as much in related lymphomas such as primary mediastinal B-cell lymphoma.
So these lymphoma cells are not just generic rebels. They look like B cells that partially changed costume, forgot their lines, and then kept the stress-response alarm blaring in the background. Older work had hinted at this odd half-plasma-cell state, but this study gives it a much sharper transcriptomic map (Casagrande et al., 2022, Munir et al., 2023).
NK cells got ghosted
Now for the second trick. NK cells are part of your immune system’s rapid-response team. They are the bouncers who do not need a full committee meeting before tossing out a suspicious guest. One reason they matter in Hodgkin lymphoma is that HRS cells often lose features that help conventional T cells recognize them, which should, in theory, make NK cells more relevant.
This paper suggests HRS cells may sidestep that problem by lowering SLAM-family ligands, including CD48. In plain English: they may be taking down some of the molecular “hey, over here, this is shady” signs that NK cells use to engage. If your immune system were a neighborhood watch, this is the equivalent of the culprit unscrewing the streetlights and taking the house numbers with them.
That fits with a broader picture from recent Hodgkin lymphoma research. Reviews over the past few years have described cHL as a disease that actively reshapes its immune neighborhood, recruiting helpful bystanders and muffling the cells most likely to kill it (Ferrarini et al., 2020, Taylor et al., 2023). More recent work on patients who resist PD-1 blockade also points to disturbed NK-cell states and wider immune rewiring, which is not exactly the kind of surprise party anyone wanted (Elhaj et al., 2024).
Why this could matter outside a sequencing lab
The obvious question is: nice molecular detective work, but does it change anything? Potentially, yes.
First, if UPR biology is helping HRS cells survive their own dysfunctional identity, that pathway could become a therapeutic weak spot. Cancer cells that live under chronic internal stress sometimes depend on stress-management pathways the way the rest of us depend on coffee and denial. Block the pathway, and the whole arrangement may wobble.
Second, the NK-cell angle matters because Hodgkin lymphoma treatment is already being reshaped by immunotherapy. PD-1 blockade has become a major part of the field, and recent clinical reporting in 2024 and 2025 keeps pushing the conversation toward smarter immune-based combinations. But not every patient responds, and not every response lasts. If HRS cells are specifically evading NK recognition, then therapies that restore those interactions, or combine checkpoint blockade with approaches that wake up innate immunity, start to look a lot more interesting.
Picture the tumor microenvironment as a sketchy neighborhood where the cops are circling the block, the street signs are wrong, and one apartment building has been quietly paying everyone to mind their own business. This study helps identify both the busted wiring inside the building and one of the tricks used to keep the patrol outside.
The big takeaway, minus the lab coat voice
What I like about this paper is that it makes Hodgkin lymphoma feel less like a vague “immune-rich cancer” and more like a specific biological setup. The HRS cell is not just hiding. It is stressed, misshapen, partly reprogrammed, and very actively managing who gets to notice.
That is a better story, scientifically speaking, because better stories are testable. If this result holds up in larger cohorts and functional follow-up studies, it could point toward two useful pressure points at once: the lymphoma cell’s own protein-stress machinery and its habit of slipping past NK cells like a guy leaving a party through the kitchen.
Cancer biology stays weird. That is one of its least charming habits. But every time a paper turns “weird” into “mapped,” the odds of finding a smarter treatment get a little better.
References
-
Roshal M, Kong IY, Dinalankara W, et al. Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response. Blood Cancer Journal. 2026. DOI: 10.1038/s41408-026-01502-1
-
Casagrande N, Borghese C, Aldinucci D. Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma. Cancers (Basel). 2022;14(10):2427. DOI: 10.3390/cancers14102427. PMCID: PMC9139207
-
Munir F, Hardit V, Sheikh IN, et al. Classical Hodgkin Lymphoma: From Past to Future - A Comprehensive Review of Pathophysiology and Therapeutic Advances. International Journal of Molecular Sciences. 2023;24(12):10095. DOI: 10.3390/ijms241210095. PMCID: PMC10298672
-
Ferrarini I, Rigo A, Visco C, Krampera M, Vinante F. The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment. Cancers (Basel). 2020;12(12):3757. DOI: 10.3390/cancers12123757. PMCID: PMC7764890
-
Taylor JG, Truelove E, Clear A, Calaminici M, Gribben JG. PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion. Haematologica. 2023;108(4):1068-1082. DOI: 10.3324/haematol.2022.280014. PMCID: PMC10071123
-
Elhaj M, et al. Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma. Nature Communications. 2024. DOI: 10.1038/s41467-024-54512-7
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.